718 results on '"Jaeger, U"'
Search Results
2. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
3. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
4. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
5. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
6. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
7. A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors
8. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
9. Tumoren bei immunsupprimierten Patienten
10. BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils
11. Lymphoplasmozytisches Lymphom/Makroglobulinämie Waldenström
12. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
13. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
14. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
15. P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
16. P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
17. Tumoren bei immunsupprimierten Patienten
18. Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study
19. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
20. Sensitization of Human Cells to Lysis by Human Complement as an Approach for Cancer Gene Therapy
21. Characterization of height-selective emitters
22. R-metHuG-CSF Combined with Chemotherapy for Treatment of Adult ALL — Pilot Study
23. Echtzeitbildverarbeitung mit Fuzzy Logic
24. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
25. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
26. Körperhöhe, Körpergewicht und Body Mass Index bei deutschen Wehrpflichtigen. Historischer Rückblick und aktueller Stand
27. 12 th Congress of the European Anthropological Association, 8.-11. September 2000 in Cambridge, England
28. Ergebnisse der Untersuchung ausgewählter Kopfmaße bei Jenaer Kindern
29. Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma: 35
30. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
31. Werden Kopfmaße von Umweltfaktoren beeinflußt?
32. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
33. SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDY
34. Säkularer Trend bei der Körperhöhe seit dem Neolithikum
35. In memoriam: Herbert Bach 14.3.1926-12.7.1996
36. Bericht über die gemeinsame Tagung des „Fachausschusses T 5.4 Anthropotechnik Lilienthal Oberth e.V.(DGLR)“ und der Arbeitsgemeinschaft „Angewandte Anthropometrie“
37. Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial
38. Intra-Arterial Calcium Gluconate Treatment After Hydrofluoric Acid Burn of the Hand
39. Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial
40. The CLL-RT1 trial : A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation
41. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
42. Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial
43. Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel
44. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
45. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
46. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
47. PET-CT-Bildgebung bei Kopf-Hals-Tumoren
48. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL)
49. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome
50. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.